Papers by Michael C. Irizarry
15 results
- AAIC 2025 Abstract
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Study in peopleBiomarkers - AAIC 2025 Abstract
Results from a Human Factor Study Supporting Safe and Effective Use of the Lecanemab Subcutaneous Autoinjector
Trial in peopleInterventions
- AAIC 2025 Abstract
DIAN‐TU‐001 Trial (Tau NexGen) Rationale and Enrollment Experience
Trial in peopleInterventions - AAIC 2025 Abstract
Subcutaneous Lecanemab: Potential Benefits and Place in Therapy
Trial in peopleInterventions - AAIC 2025 Abstract
Lecanemab Subcutaneous Formulation for Maintenance Dosing in Early Alzheimer’s Disease (AD)
Computational studyInterventions - AAIC 2025 Abstract
Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab Formulation
Trial in peopleInterventions - AAIC 2025 Abstract
Influence of Demographics and Scan Time on MK6240 Off‐Target Signal and Reference Region Selection
Study in peopleBiomarkers - AAIC 2025 Abstract
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Study in peopleBiomarkers - AAIC 2025 Abstract
Target Engagement of Lecanemab on CSF Aβ Protofibril Toxic Species in Clarity AD
Trial in peopleInterventions